CMMI
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Drug shortages, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Preventative, Reference Pricing
Caught my eye — 5/16/25
Read more: Caught my eye — 5/16/25This week I’ve repeatedly spoken to groups about the President’s Executive Order (EO) on Most Favored Nation (MFN) pricing and I feel a little vulnerable. I am often “authentic” in my explanations. I recognize that to many people I seem biased on a lot of issues but, in my defense, I find most politics maddening…
-
340B, Biosimilars, CMMI, Drug Prices, Generics, Healthcare Costs, Importation, Insulin, Medicaid, Pharmacy Benefit ManagersDon’t Call it a Comeback
Read more: Don’t Call it a ComebackLet’s wrap up my musings on the President’s Executive Order (EO). Medicaid. Section 6 of the EO directs the Office of Management and Budget (OMB) Director, the Assistant to the President for Domestic Policy, and the Assistant to the President for Economic Policy, in coordination with the Secretary of Health and Human Services (HHS), to…
-
Caught my eye — 5/2/25
Read more: Caught my eye — 5/2/25It has been a week that has rushed by and yet Monday feels like very long time ago. You know these kinds of weeks. So, let’s do a quick roundup of what made me pause between the stimulation overload of Vegas. And So it Begins? The Food and Drug Administration (FDA) has suffered huge staffing…
-
Catch as Catch Can
Read more: Catch as Catch CanSection 4 of the President’s Executive Order (EO) on drug pricing aims to reduce the high-cost drugs for seniors through the development and implementation of a payment model. It is very light on details; basically a title and one run-on sentence. So wide in scope you could drive a truck through it, but let’s pull…
-
340B, Biosimilars, Caught my eye, CMMI, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit ManagersCaught my eye — 3/14/25
Read more: Caught my eye — 3/14/25With the exception of the ending of demos/models at the Centers for Medicare & Medicaid Innovation (CMMI), most of the news kind of rolled over me this week. So, instead, here is a capture of what is rattling around my chamber of health policy worries. Who’s on first? What’s on second? I don’t know ……
-
Affordable Care Act, Caught my eye, Cell and Gene, CMMI, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit ManagersCaught my eye — 2/7/25
Read more: Caught my eye — 2/7/25In the DC area, with many family, friends and neighbors working for the federal government, these last few weeks have felt downright crappy. Furloughs, contracts being upended, fear about what’s next — all for people who love their jobs serving the public. It isn’t a fork in the road, it feels like a game of…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Healthcare Costs, Obesity, Pharmacy Benefit ManagersCaught my eye — 9/27/24
Read more: Caught my eye — 9/27/24If you haven’t trained your teams on Medicare Part D changes for 2025, hop to it. Or reach out to me. These are January 1 issues and we’re about to hit October…. Let me clear my throat. The STAT news breaking news headline read “Sanders says pharmacy benefit managers (PBMs) won’t penalize Novo for cutting…
-
Caught my eye — 06/07/24
Read more: Caught my eye — 06/07/24A relatively quiet week around these parts. I think everyone is so ASCO’d and BIO’d that policy is taking a quick breather. A PDAB will do you. The National Pharmaceutical Council put out a nice round-up comparing four prescription drug affordability boards. The chart is my favorite part – Extra, extra. Elevance Health, a health…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Drug shortages, Health Equity, Inflation Reduction Act, Medicare Part D, ObesityCaught my eye — 4/5/24
Read more: Caught my eye — 4/5/24Ruling It. Yesterday afternoon, the Centers for Medicare & Medicaid Services released the MA/Part D final rule. Personally, most of it was not up my alley but I did read over the changes to the changes to an approved formulary sections. In December 2022, CMS proposed allowing immediate substitution of interchangeable biosimilars or branded biologics…
-
Caught my eye — 3/22/24
Read more: Caught my eye — 3/22/24If you’re one of those people who is working from the couch today, I salute you. It really is the most fun day of sports. I was mocked for the way I picked my bracket (where wouId I rather live?) but I had a clean bracket until Kentucky. I blame my newfound like of bourbon.…
Latest news
- Caught my eye — 5/16/25
- Initial Take on MFN Executive Order, Part II
- Caught my eye — 5/09/25
- Don’t Call it a Comeback
- Caught my eye — 5/2/25
Categories
- 340B (38)
- Affordable Care Act (5)
- Alzheimer's (6)
- Biosimilars (22)
- Caught my eye (67)
- Cell and Gene (2)
- Chevron Deference (2)
- CMMI (14)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (36)
- Drug shortages (10)
- DTC (2)
- Employers (8)
- Generics (6)
- Health Equity (3)
- Healthcare Costs (30)
- ICER (10)
- Importation (4)
- Inflation Reduction Act (50)
- Insulin (5)
- IP (3)
- Long term care (1)
- Medicaid (7)
- Medicare Advantage (16)
- Medicare Negotiation (52)
- Medicare Part D (47)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (9)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (32)
- Preventative (2)
- Reference Pricing (8)
- State-based Reform (16)
- Supply Chain (2)
- Uncategorized (7)
- Utilization Management (1)
- Vaccines (4)
- Value (13)